FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1946552810> ?p ?o ?g. }

• W1946552810 abstract "Background Myelodysplastic syndromes (MDS) are a heterogeneous group of haematological diseases which are characterised by a uni‐ or multilineage dysplasia of haematological stem cells. Standard treatment is supportive care of the arising symptoms including red blood cell transfusions or the administration of erythropoiesis‐stimulating agents (ESAs) in the case of anaemia or the treatment with granulocyte (G‐CSF) and granulocyte‐macrophage colony stimulating factors (GM‐CSF) in cases of neutropenia. Objectives The objective of this review is to assess the evidence for the treatment of patients with MDS with G‐CSF and GM‐CSF in addition to standard therapy in comparison to the same standard therapy or the same standard therapy and placebo. Search methods We searched MEDLINE (from 1950 to 3 December 2015) and CENTRAL (Cochrane Central Register of Controlled Trials until 3 December 2015), as well as conference proceedings (American Society of Hematology, American Society of Clinical Oncology, European Hematology Association, European Society of Medical Oncology) for randomised controlled trials (RCTs). Two review authors independently screened search results. Selection criteria We included RCTs examining G‐CSF or GM‐CSF in addition to standard therapy in patients with newly diagnosed MDS. Data collection and analysis We used hazard ratios (HR) as effect measure for overall survival (OS), progression‐free survival (PFS) and time to progression, and risk ratios for response rates, adverse events, antibiotic use and hospitalisation. Two independent review authors extracted data and assessed risk of bias. Investigators of two trials were contacted for subgroup information, however, no further data were provided. G‐CSF and GM‐CSF were analysed separately. Main results We screened a total of 566 records. Seven RCTs involving 486 patients were identified, but we could only meta‐analyse the two evaluating GM‐CSF. We judged the potential risk of bias of these trials as unclear, mostly due to missing information. All trials were randomised and open‐label studies. However, three trials were published as abstracts only, therefore we were not able to assess the potential risk of bias for these trials in detail. Overall, data were not reported in a comparable way and patient‐related outcomes like survival, time to progression to acute myeloid leukaemia (AML) or the incidence of infections was reported in two trials only. Five RCTs (N = 337) assessed the efficacy of G‐CSF in combination with standard therapy (supportive care, chemotherapy or erythropoietin). We were not able to perform meta‐analyses for any of the pre‐planned outcomes due to inconsistent and insufficient reporting of data. There is no evidence for a difference for overall survival (hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.44 to 1.47), progression‐free survival (only P value provided), progression to AML, incidence of infections and number of red blood transfusions (average number of 12 red blood cell transfusions in each arm). We judged the quality of evidence for all these outcomes as very low, due to very high imprecision and potential publication bias, as three trials were published as abstracts only. Data about quality of life and serious adverse events were not reported in any of the included trials. Two RCTs (N = 149) evaluated GM‐CSF in addition to standard therapy (chemotherapy). For mortality (two RCTs; HR 0.88, 95% CI 0.62 to 1.26), we found no evidence for a difference (low‐quality evidence). Data for progression‐free survival and serious adverse events were not comparable across both studies, without evidence for a difference between both arms (low‐quality evidence). For infections, red blood cell and platelet transfusions, we found no evidence for a difference, however, these outcomes were reported by one trial only (low‐quality evidence). Time to progression to AML and quality of life were not reported at all. Moreover, we identified two cross‐over trials, including 244 patients and evaluating GM‐CSF versus placebo, without publishing results for each arm before crossing over. In addition, we identified two ongoing studies, one of which was discontinued due to withdrawal of pharmaceutical support, the other was terminated early, both without publishing results. Authors' conclusions Although we identified seven trials with a total number of 486 patients, and two unpublished, prematurely finished studies, this systematic review mainly shows that there is a substantial lack of data, which might inform the use of G‐CSF and GM‐CSF for the prevention of infections, prolonging of survival and improvement of quality of life. The impact on progression to AML remains unclear." @default.
• W1946552810 created "2016-06-24" @default.
• W1946552810 creator A5000205027 @default.
• W1946552810 creator A5041461263 @default.
• W1946552810 creator A5046329402 @default.
• W1946552810 creator A5057387418 @default.
• W1946552810 creator A5091567011 @default.
• W1946552810 date "2016-02-16" @default.
• W1946552810 modified "2023-10-16" @default.
• W1946552810 title "Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes" @default.
• W1946552810 cites W1220491257 @default.
• W1946552810 cites W1514782697 @default.
• W1946552810 cites W1541533982 @default.
• W1946552810 cites W16058864 @default.
• W1946552810 cites W173382625 @default.
• W1946552810 cites W187238933 @default.
• W1946552810 cites W1939389201 @default.
• W1946552810 cites W1970838494 @default.
• W1946552810 cites W1978324270 @default.
• W1946552810 cites W1978522934 @default.
• W1946552810 cites W1979820704 @default.
• W1946552810 cites W1988762737 @default.
• W1946552810 cites W1995891393 @default.
• W1946552810 cites W1996887331 @default.
• W1946552810 cites W2004089260 @default.
• W1946552810 cites W2010680827 @default.
• W1946552810 cites W2012058737 @default.
• W1946552810 cites W2014190277 @default.
• W1946552810 cites W2025433645 @default.
• W1946552810 cites W2029573304 @default.
• W1946552810 cites W2030437009 @default.
• W1946552810 cites W2039847332 @default.
• W1946552810 cites W2050699744 @default.
• W1946552810 cites W2058820265 @default.
• W1946552810 cites W2061675161 @default.
• W1946552810 cites W2063823548 @default.
• W1946552810 cites W2067804675 @default.
• W1946552810 cites W2071496654 @default.
• W1946552810 cites W2075642745 @default.
• W1946552810 cites W2078843668 @default.
• W1946552810 cites W2087211634 @default.
• W1946552810 cites W2088095316 @default.
• W1946552810 cites W2110895847 @default.
• W1946552810 cites W2110949925 @default.
• W1946552810 cites W2117674210 @default.
• W1946552810 cites W2133493764 @default.
• W1946552810 cites W2140559350 @default.
• W1946552810 cites W2142195688 @default.
• W1946552810 cites W2147822765 @default.
• W1946552810 cites W2151116678 @default.
• W1946552810 cites W2156098321 @default.
• W1946552810 cites W2159156084 @default.
• W1946552810 cites W2165036959 @default.
• W1946552810 cites W2170131366 @default.
• W1946552810 cites W2270245312 @default.
• W1946552810 cites W2330558238 @default.
• W1946552810 cites W2411616922 @default.
• W1946552810 cites W2412900863 @default.
• W1946552810 cites W2417673194 @default.
• W1946552810 cites W2464682244 @default.
• W1946552810 cites W2468996569 @default.
• W1946552810 cites W2572119714 @default.
• W1946552810 cites W2979450469 @default.
• W1946552810 cites W4232645703 @default.
• W1946552810 cites W4242752547 @default.
• W1946552810 doi "https://doi.org/10.1002/14651858.cd009310.pub2" @default.
• W1946552810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26880256" @default.
• W1946552810 hasPublicationYear "2016" @default.
• W1946552810 type Work @default.
• W1946552810 sameAs 1946552810 @default.
• W1946552810 citedByCount "8" @default.
• W1946552810 countsByYear W19465528102016 @default.
• W1946552810 countsByYear W19465528102018 @default.
• W1946552810 countsByYear W19465528102021 @default.
• W1946552810 countsByYear W19465528102022 @default.
• W1946552810 countsByYear W19465528102023 @default.
• W1946552810 crossrefType "journal-article" @default.
• W1946552810 hasAuthorship W1946552810A5000205027 @default.
• W1946552810 hasAuthorship W1946552810A5041461263 @default.
• W1946552810 hasAuthorship W1946552810A5046329402 @default.
• W1946552810 hasAuthorship W1946552810A5057387418 @default.
• W1946552810 hasAuthorship W1946552810A5091567011 @default.
• W1946552810 hasConcept C126322002 @default.
• W1946552810 hasConcept C143998085 @default.
• W1946552810 hasConcept C168563851 @default.
• W1946552810 hasConcept C194409129 @default.
• W1946552810 hasConcept C197934379 @default.
• W1946552810 hasConcept C207103383 @default.
• W1946552810 hasConcept C2776694085 @default.
• W1946552810 hasConcept C2777063308 @default.
• W1946552810 hasConcept C2777767877 @default.
• W1946552810 hasConcept C2780007613 @default.
• W1946552810 hasConcept C2780817109 @default.
• W1946552810 hasConcept C44249647 @default.
• W1946552810 hasConcept C535046627 @default.
• W1946552810 hasConcept C71924100 @default.
• W1946552810 hasConceptScore W1946552810C126322002 @default.
• W1946552810 hasConceptScore W1946552810C143998085 @default.
• W1946552810 hasConceptScore W1946552810C168563851 @default.
• W1946552810 hasConceptScore W1946552810C194409129 @default.

• next